PP_1170x120_10-25-21

first-in-human trial of a peripheral sirolimus drug-coated balloon

BD launches first-in-human trial of sirolimus drug-coated balloon

BD launches first-in-human trial of sirolimus drug-coated balloon

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) has announced the start of enrollment in a first-in-human trial of a peripheral sirolimus drug-coated balloon (DCB). BD is a pioneer in DCB technology as the first to gain U.S. FDA approval for a paclitaxel DCB.  BD’s Lutonix, which received FDA approval in 2014, is celebrating

Adheris Health